This is a Non-interventional, Study to Assess Demographic Characteristics and Patient Reported Outcomes in China Patients With SEA Treated With Benralizumab

Inclusion criteria -Patients are eligible to be included in the study only if all of the following criteria apply: * Patients must to be 12 years old (inclusive) at the time of signing the informed consent. * Patients with severe eosinophilic asthma prescribed with benralizumab at the discretion of the clinician. * Blood EOS≥150/ul in the 3 months prior to or EOS≥300/ul in the 1 year prior to the time of signing the informed consent. * Participating patients and/or their legally authorized representative must provide signed and dated written informed consent form prior to any study specific procedures. Exclusion criteria -Patients should not enter the study if any of the following exclusion criteria are fulfilled: * Patients currently participating in any other clinical trial. * Known history of allergy or reaction to any component of the study treatment formulation. * Malignancy of any kind. * Patients with prior or ongoing treatment with benralizumab.